Activity
Mon
Wed
Fri
Sun
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
What is this?
Less
More

Owned by Kiki

We are here for you because we've been there. Get support, education, resources and more!!!

406 contributions to Peptide Resource Center
Spoiler alert: The scoop on Orexin B and Orexin A
⚠️ Dealbreaker: **Evidence status:** Endogenous peptide, well-studied system. Shown not to reach the brain from peripheral injection, so don't. ❇️ What it is Orexin B, also called hypocretin-2, is a natural 28-amino-acid neuropeptide made in the lateral hypothalamus. It's one of two orexins cut from the same precursor protein, prepro-orexin. The other is orexin A. ❇️ How it works The orexin system is the brain's main wakefulness and arousal regulator. It also influences feeding, energy balance, motivation, and reward. There are two receptors, OX1R and OX2R. Orexin A binds both at roughly equal strength. Orexin B is selective for OX2R, with around tenfold preference for it. OX2R is the receptor most tied to the sleep-wake switch, which is why pharmaceutical companies developing narcolepsy drugs have gone after OX2R specifically with small molecules like TAK-925 and TAK-861. The loss of orexin-producing neurons is what causes narcolepsy type 1. Mass spectrometry work in cerebrospinal fluid has confirmed that all orexin species are significantly reduced in narcolepsy type 1 compared with narcolepsy type 2 or idiopathic hypersomnia. ❇️ What the research shows, and a critical limitation Here's the single most important fact about orexin B, and it's one that often gets left out. ➡ Orexin B does not cross the blood-brain barrier when given peripherally. A direct comparison study found orexin A is highly lipophilic and crosses the barrier readily by simple diffusion. Orexin B had a partition coefficient roughly eight times lower and was rapidly degraded in blood, to the point that no intact orexin B could be detected in brain tissue after peripheral injection. That finding shapes everything else. 📢 The promising cognitive and wakefulness research on intranasal orexin, including increased acetylcholine and glutamate release in the prefrontal cortex and improvements in cognitive function in sleep-deprived and narcoleptic subjects, was done with orexin A, not orexin B. Reviews of intranasal orexin for age-related cognitive dysfunction note that the OX1 receptor mediates most of those responses, which is the receptor orexin B is relatively weak at.
1
0
Adamax in depth
❇️ **Evidence status:** No human or dedicated animal studies. All claims extrapolated from its parent compound, Semax. ❇️ What it is Adamax is a synthetic modification of Semax, the Russian-developed nootropic peptide. Chemically it's written as Ac-MEHFPGP-adamantyl, sometimes described as N-Acetyl Semax Adamantane. It's occasionally called "Super Semax" in research circles. ❇️ How it works The starting point is Semax, a fragment of the ACTH hormone (specifically the ACTH 4-7 region, sequence Met-Glu-His-Phe-Pro-Gly-Pro). Semax has decades of Russian clinical use and research behind it, mostly in stroke rehabilitation and cognitive function, and it's thought to work partly by raising BDNF. Adamax adds two changes to that backbone. An acetyl group at one end slows enzymatic breakdown. An adamantane group, which is a rigid cage-shaped carbon structure, is attached at the other end. Adamantane is very fat-soluble, and the theory is that it helps the molecule cross cell membranes and the blood-brain barrier more readily, while also resisting degradation. The result should, in theory, be a longer-lasting and more brain-penetrant version of Semax. ❇️ What the research shows This is where honesty matters. There are no published human trials on Adamax specifically. There is no dedicated clinical dataset. Essentially every claim made about Adamax is extrapolated from Semax research or from general work on adamantane-modified neurotrophic peptides. Those adamantane-peptide designs do have preclinical support for improving learning, neurogenesis, and synaptogenesis in animal models. But that's the compound class, not this compound. The Semax foundation is more solid. The long-running Russian work, including Ashmarin's review of fifteen years of Semax design and study, reported that intranasal Semax affected working memory and attention, with effects described as lasting on the order of a day. So: a well-studied parent compound, a chemically sensible modification, and no direct evidence.
0
0
So whatever happened to Bioglutide?
❇️ NA-931 (Bioglutide) ❇️ **Evidence status:** Human clinical trial data — company-reported Phase 2 (n=125, 13 weeks). Oral formulation. ❇️ What it is NA-931 is an experimental weight-loss compound developed by Biomed Industries, which also calls it Bioglutide. It's unusual among obesity drugs because it hits four receptors at once and because it was designed as an oral capsule rather than an injection. ❇️ How it works Most of the current weight-loss drugs work on one or two hormone receptors. Semaglutide works on GLP-1. Tirzepatide works on GLP-1 and GIP. NA-931 targets four: GLP-1, GIP, glucagon, and IGF-1. The IGF-1 piece is the interesting part. IGF-1 signaling is tied to muscle maintenance, and the company's stated goal was weight loss without the muscle loss that often comes with aggressive calorie restriction or strong GLP-1 agonism. ❇️ What the research shows NA-931 has real human trial data, which separates it from most research compounds. The Phase 2 trial ran 13 weeks, randomized, double-blind, placebo-controlled, with 125 adults who were either obese (BMI 30 or above) or overweight (BMI 27 or above with a weight-related condition). At the top dose tested, 150 mg once daily, mean weight loss was reported in the 13.8 to 14.8 percent range by week 13, roughly 12 percentage points better than placebo. Up to 72 percent of people on the drug lost 12 percent or more of their body weight, compared with 2 percent on placebo. Side effects were described as mostly mild, with less gastrointestinal trouble than is typical for injectable GLP-1 drugs. The company has also run a Phase 2 protocol combining NA-931 with tirzepatide, and has said it's moving toward Phase 3. A caution on reading these results: all of this comes from company presentations at conferences (ADA 2025, EASD 2025) and company press releases. That's normal for this stage, but it isn't the same as full peer-reviewed publication with independent scrutiny. ❇️ Protocol data from the literature
0
0
Back to our roots! Education is the foundation of PRC
Most writing about research peptides has the same shape. A mechanism is described in confident language, a benefit is implied, and a dosing protocol appears at the bottom. What's almost always missing is the part that matters most: where the evidence came from, and what it doesn't cover. I'll be posting nine daily articles which are written the other way around. The point isn't to tell you what to do with each compound. It's to let you see exactly how much is known, how it was learned, and where the floor drops out. ❇️ The evidence isn't all the same kind The nine compounds I'll talk about span an enormous range, and lumping them together as "research peptides" hides that. Roughly: ➡ Human clinical trial data exists** for NA-931, VIP (aviptadil), and larazotide acetate. These have been given to people in controlled studies with published results, dose-finding, and documented side effects. Larazotide and VIP have been through Phase 2 and beyond. ➡ **Animal data only** for colivelin, DNSP-11, and Epobis. These have real, often quite good research behind them — but it ends at rats and mice, and in several cases the compound was delivered directly into brain tissue by surgery. No human has been dosed in a published study. ➡ **Essentially no direct data** for Adamax and Orexin B as used. Adamax has no dedicated human or animal study of its own; everything claimed about it is inherited from its parent compound, Semax. Orexin B has decades of research on the orexin *system*, but the cognitive work people cite was done with orexin A, and orexin B specifically has been shown not to reach the brain from peripheral injection. ➡ **Data with a problem attached** for Dihexa. Rodent results exist, but the paper establishing its mechanism was retracted over data integrity, and the pathway it targets is a known cancer pathway. 🔸 A protocol list would flatten all of that into one format. These articles don't. 🔸 ❇️ What "research use only" actually means The label is usually read as a legal formality. It isn't only that. For most compounds in this category it's an accurate description of the evidence: no one has established a safe human dose, because no one has run the study that would establish it.
1
0
How is everyone?!
With so many changes happening in the peptide community, how is everyone holding up?
1
0
How is everyone?!
1-10 of 406
Kiki Riki
6
1,442 points to level up
@kiki-riki-5877
The one-stop destination in your research peptide journey. Find sources/info so you can focus on what matters most, YOUR research.

Active 1d ago
Joined Nov 28, 2025